Several major financial firms, including TD Cowen, Stifel, Goldman Sachs, and Barclays, have increased their price targets for Thermo Fisher Scientific. These upward revisions indicate a positive shift in analyst sentiment regarding the company's market position and future financial performance, suggesting potential upside for the stock.
On October 22, 2026, multiple prominent financial firms, including TD Cowen, Stifel, Goldman Sachs, and Barclays, raised their price targets for Thermo Fisher Scientific. This collective upward adjustment signals a strengthening positive outlook from analysts on the company's market standing and financial prospects. For traders, this development presents a short-term opportunity as the increased price targets could lead to positive momentum and investor interest in TMO shares. In the long term, sustained positive analyst sentiment, if backed by strong company performance, could contribute to continued stock appreciation, though the primary risk remains the company's ability to meet or exceed these elevated expectations.